As obese humans show lower circulating glucagon-like peptide-1 (GLP-1), similar to that of PYY, it has been thought that the resistance to this gut hormone contributes to the obesity
It is among a class of medications known as GLP-1s, renowned for their effectiveness in facilitating weight loss by regulating appetite and reducing caloric intake
However, the high cost derived from the purification techniques and the high doses required due to the instability of these molecules in vivo are the two most significant points of concern [23]
The presence of anti-thyroid antibodies at baseline is a risk factor for destructive thyroiditis and/or hypothyroidism induced by anti-PD-1 antibodies TgAb and/or TPOAb were present at baseline in 44 patients (18 treated with pembrolizumab, 26 with nivolumab) (Abs-positive group)
Fluid Composition: Some people are sensitive to specific electrolytes or ingredients in IV solutions, such as sodium chloride or potassium
This story was originally published July 8, 2024